![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PMAIP1 |
Gene summary for PMAIP1 |
![]() |
Gene information | Species | Human | Gene symbol | PMAIP1 | Gene ID | 5366 |
Gene name | phorbol-12-myristate-13-acetate-induced protein 1 | |
Gene Alias | APR | |
Cytomap | 18q21.32 | |
Gene Type | protein-coding | GO ID | GO:0001666 | UniProtAcc | A0A0S2Z490 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5366 | PMAIP1 | C06 | Human | Oral cavity | OSCC | 1.02e-06 | 1.59e+00 | 0.2699 |
5366 | PMAIP1 | C08 | Human | Oral cavity | OSCC | 1.82e-55 | 2.44e+00 | 0.1919 |
5366 | PMAIP1 | C86 | Human | Oral cavity | OSCC | 1.21e-10 | 3.17e+00 | 0.161 |
5366 | PMAIP1 | C09 | Human | Oral cavity | OSCC | 6.76e-17 | 1.14e+00 | 0.1431 |
5366 | PMAIP1 | LN22 | Human | Oral cavity | OSCC | 7.87e-16 | 2.21e+00 | 0.1733 |
5366 | PMAIP1 | LN38 | Human | Oral cavity | OSCC | 4.86e-11 | 2.62e+00 | 0.168 |
5366 | PMAIP1 | LN46 | Human | Oral cavity | OSCC | 2.27e-55 | 3.27e+00 | 0.1666 |
5366 | PMAIP1 | LP15 | Human | Oral cavity | LP | 5.52e-12 | 2.59e+00 | 0.2174 |
5366 | PMAIP1 | LP17 | Human | Oral cavity | LP | 3.04e-09 | 1.95e+00 | 0.2349 |
5366 | PMAIP1 | SYSMH1 | Human | Oral cavity | OSCC | 7.66e-13 | 7.90e-01 | 0.1127 |
5366 | PMAIP1 | SYSMH2 | Human | Oral cavity | OSCC | 6.43e-49 | 2.50e+00 | 0.2326 |
5366 | PMAIP1 | SYSMH3 | Human | Oral cavity | OSCC | 8.18e-38 | 1.47e+00 | 0.2442 |
5366 | PMAIP1 | SYSMH4 | Human | Oral cavity | OSCC | 1.23e-44 | 1.46e+00 | 0.1226 |
5366 | PMAIP1 | SYSMH6 | Human | Oral cavity | OSCC | 1.06e-26 | 1.33e+00 | 0.1275 |
5366 | PMAIP1 | GSM5252126_BPH283PrGF_Via | Human | Prostate | BPH | 1.55e-10 | 1.10e+00 | -0.1771 |
5366 | PMAIP1 | GSM5252127_BPH283PrSF_Via | Human | Prostate | BPH | 1.48e-12 | 1.14e+00 | -0.1453 |
5366 | PMAIP1 | GSM5252128_BPH327PrGF_Via | Human | Prostate | BPH | 3.50e-10 | 8.52e-01 | -0.1688 |
5366 | PMAIP1 | GSM5252132_BPH389PrGF | Human | Prostate | BPH | 9.84e-08 | 1.44e+00 | -0.2247 |
5366 | PMAIP1 | GSM5252133_BPH389PrSF | Human | Prostate | BPH | 1.70e-04 | 1.51e+00 | -0.2027 |
5366 | PMAIP1 | GSM5252134_BPH511PrG_Fcol_3GEX | Human | Prostate | BPH | 3.70e-07 | 7.73e-01 | -0.1433 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00971939 | Breast | Precancer | intrinsic apoptotic signaling pathway | 59/1080 | 288/18723 | 8.07e-18 | 3.60e-15 | 59 |
GO:20012339 | Breast | Precancer | regulation of apoptotic signaling pathway | 65/1080 | 356/18723 | 7.70e-17 | 3.17e-14 | 65 |
GO:20012429 | Breast | Precancer | regulation of intrinsic apoptotic signaling pathway | 41/1080 | 164/18723 | 6.48e-16 | 2.31e-13 | 41 |
GO:00525479 | Breast | Precancer | regulation of peptidase activity | 71/1080 | 461/18723 | 2.72e-14 | 6.94e-12 | 71 |
GO:00525489 | Breast | Precancer | regulation of endopeptidase activity | 67/1080 | 432/18723 | 1.06e-13 | 2.36e-11 | 67 |
GO:00362939 | Breast | Precancer | response to decreased oxygen levels | 53/1080 | 322/18723 | 4.09e-12 | 6.84e-10 | 53 |
GO:00016669 | Breast | Precancer | response to hypoxia | 51/1080 | 307/18723 | 7.33e-12 | 1.11e-09 | 51 |
GO:00704829 | Breast | Precancer | response to oxygen levels | 55/1080 | 347/18723 | 7.47e-12 | 1.11e-09 | 55 |
GO:20001169 | Breast | Precancer | regulation of cysteine-type endopeptidase activity | 43/1080 | 235/18723 | 1.30e-11 | 1.83e-09 | 43 |
GO:00068398 | Breast | Precancer | mitochondrial transport | 45/1080 | 254/18723 | 1.37e-11 | 1.88e-09 | 45 |
GO:00432819 | Breast | Precancer | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 40/1080 | 209/18723 | 1.59e-11 | 2.07e-09 | 40 |
GO:00362948 | Breast | Precancer | cellular response to decreased oxygen levels | 31/1080 | 161/18723 | 2.61e-09 | 2.11e-07 | 31 |
GO:00714538 | Breast | Precancer | cellular response to oxygen levels | 32/1080 | 177/18723 | 7.32e-09 | 5.52e-07 | 32 |
GO:00458629 | Breast | Precancer | positive regulation of proteolysis | 51/1080 | 372/18723 | 7.77e-09 | 5.70e-07 | 51 |
GO:00714565 | Breast | Precancer | cellular response to hypoxia | 29/1080 | 151/18723 | 8.98e-09 | 6.50e-07 | 29 |
GO:20012445 | Breast | Precancer | positive regulation of intrinsic apoptotic signaling pathway | 17/1080 | 58/18723 | 1.59e-08 | 1.12e-06 | 17 |
GO:00109529 | Breast | Precancer | positive regulation of peptidase activity | 33/1080 | 197/18723 | 3.01e-08 | 1.89e-06 | 33 |
GO:00086378 | Breast | Precancer | apoptotic mitochondrial changes | 23/1080 | 107/18723 | 3.44e-08 | 2.12e-06 | 23 |
GO:00349769 | Breast | Precancer | response to endoplasmic reticulum stress | 38/1080 | 256/18723 | 7.89e-08 | 4.60e-06 | 38 |
GO:00518816 | Breast | Precancer | regulation of mitochondrial membrane potential | 18/1080 | 74/18723 | 1.45e-07 | 7.82e-06 | 18 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa042108 | Breast | Precancer | Apoptosis | 25/684 | 136/8465 | 7.61e-05 | 6.87e-04 | 5.26e-04 | 25 |
hsa052036 | Breast | Precancer | Viral carcinogenesis | 27/684 | 204/8465 | 7.19e-03 | 4.06e-02 | 3.11e-02 | 27 |
hsa0421013 | Breast | Precancer | Apoptosis | 25/684 | 136/8465 | 7.61e-05 | 6.87e-04 | 5.26e-04 | 25 |
hsa0520312 | Breast | Precancer | Viral carcinogenesis | 27/684 | 204/8465 | 7.19e-03 | 4.06e-02 | 3.11e-02 | 27 |
hsa0421022 | Breast | IDC | Apoptosis | 31/867 | 136/8465 | 1.34e-05 | 1.61e-04 | 1.20e-04 | 31 |
hsa0520322 | Breast | IDC | Viral carcinogenesis | 34/867 | 204/8465 | 2.82e-03 | 1.86e-02 | 1.39e-02 | 34 |
hsa041157 | Breast | IDC | p53 signaling pathway | 16/867 | 74/8465 | 2.86e-03 | 1.86e-02 | 1.39e-02 | 16 |
hsa052109 | Breast | IDC | Colorectal cancer | 17/867 | 86/8465 | 5.70e-03 | 3.13e-02 | 2.34e-02 | 17 |
hsa0421032 | Breast | IDC | Apoptosis | 31/867 | 136/8465 | 1.34e-05 | 1.61e-04 | 1.20e-04 | 31 |
hsa0520332 | Breast | IDC | Viral carcinogenesis | 34/867 | 204/8465 | 2.82e-03 | 1.86e-02 | 1.39e-02 | 34 |
hsa0411512 | Breast | IDC | p53 signaling pathway | 16/867 | 74/8465 | 2.86e-03 | 1.86e-02 | 1.39e-02 | 16 |
hsa0521014 | Breast | IDC | Colorectal cancer | 17/867 | 86/8465 | 5.70e-03 | 3.13e-02 | 2.34e-02 | 17 |
hsa0421041 | Breast | DCIS | Apoptosis | 29/846 | 136/8465 | 5.92e-05 | 5.97e-04 | 4.40e-04 | 29 |
hsa0520341 | Breast | DCIS | Viral carcinogenesis | 34/846 | 204/8465 | 1.88e-03 | 1.27e-02 | 9.33e-03 | 34 |
hsa0411521 | Breast | DCIS | p53 signaling pathway | 16/846 | 74/8465 | 2.23e-03 | 1.47e-02 | 1.08e-02 | 16 |
hsa0521024 | Breast | DCIS | Colorectal cancer | 16/846 | 86/8465 | 1.03e-02 | 4.50e-02 | 3.32e-02 | 16 |
hsa0421051 | Breast | DCIS | Apoptosis | 29/846 | 136/8465 | 5.92e-05 | 5.97e-04 | 4.40e-04 | 29 |
hsa052035 | Breast | DCIS | Viral carcinogenesis | 34/846 | 204/8465 | 1.88e-03 | 1.27e-02 | 9.33e-03 | 34 |
hsa0411531 | Breast | DCIS | p53 signaling pathway | 16/846 | 74/8465 | 2.23e-03 | 1.47e-02 | 1.08e-02 | 16 |
hsa0521034 | Breast | DCIS | Colorectal cancer | 16/846 | 86/8465 | 1.03e-02 | 4.50e-02 | 3.32e-02 | 16 |
Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PMAIP1 | SNV | Missense_Mutation | novel | c.4C>T | p.Pro2Ser | p.P2S | Q13794 | protein_coding | deleterious(0.01) | possibly_damaging(0.561) | TCGA-22-5479-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | carboplatin | SD |
PMAIP1 | SNV | Missense_Mutation | novel | c.97G>A | p.Gly33Arg | p.G33R | Q13794 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CR-7383-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | paclitaxel | PR |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5366 | PMAIP1 | CLINICALLY ACTIONABLE | BORTEZOMIB | BORTEZOMIB | 16024631 |
Page: 1 |